A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
Phase of Trial: Phase I
Latest Information Update: 23 Feb 2010
At a glance
- Drugs HIV gp120 vaccine (Primary) ; Alum; QS 21
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 28 Sep 2008 Actual initiation date added as 1 Dec 1998 as reported by ClinicalTrials.gov.
- 28 Sep 2008 Actual end date added as 1 Mar 2000 as reported by ClinicalTrials.gov.
- 28 Sep 2008 Status changed from active, no longer recruiting to completed.